1.1 	A bill for an act
1.2 	relating to health; requiring informed consent for certain vaccines manufactured 
1.3 	with or containing human DNA; proposing coding for new law in Minnesota 
1.4 	Statutes, chapter 145.
1.5 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 	Section 1. [145.669] HUMAN DNA VACCINES; INFORMED CONSENT 
1.7 	REQUIRED.
1.8 		Subdivision 1.Informed consent. The Minnesota Informed Consent Form must 
1.9 	be given to any patient or, in the case of a minor, the patient's parent or legal guardian, 
1.10 	if the patient is offered vaccines or medicines manufactured with or containing human 
1.11 	fetal or embryonic cell components, deoxyribonucleic acid (DNA), recombinant DNA, 
1.12 	monoclonal antibodies, proteins, or any other components derived from fetal sources. The 
1.13 	consent form must be made available on the Department of Health's Web site for use 
1.14 	by providers.
1.15 		Subd. 2.Form. The form on the Department of Health's Web site must include 
1.16 	the following information:
1.17 	"Minnesota Informed Consent Form
1.18 	You are entitled to know that the following immunizations or medicines are 
1.19 	developed by using cell lines obtained from electively aborted fetuses. These products 
1.20 	contain residual DNA or cell components and proteins from a fetal cell line. In some cases 
1.21 	there may be an alternative that does not use residual human fetal material.

1.22	Disease
	Brand Name(s)
	Alternative
	
1.23	Chickenpox
	Varivax
	none in the United States
	
1.24	Hepatitis-A
	Vaqta, Havrix
	none in the United States
	
1.25	Hepatitis-A+B
	Twinrix
	Hepatitis B separately
	
2.1
2.2	Measles, mumps, rubella
	MMR II
	measles, mumps separately; 
none for rubella
	
2.3
2.4	Polio
	Pentacel
	Pediarix or any polio, DTaP, 
HiB separately
	
2.5	Rabies
	Imovax
	RabAvert
	
2.6	Shingles
	Zostavax
	none in the United States
	
2.7 	This form does not replace the Vaccine Information Statements required by the 
2.8 	Centers for Disease Control."
2.9 	This form must be updated by the Department of Health in the event that future 
2.10 	vaccines or medicines become available that contain residual DNA or cell components 
2.11 	and proteins from a fetal cell line.